Egrifta tesamorelin: Phase II data

A double-blind, U.S. Phase II trial in 60 obese patients with moderate growth hormone deficiency showed that once-daily 2 mg subcutaneous tesamorelin significantly reduced visceral fat by 19%, cIMT by 6% and triglycerides by 20% at 1 year vs. placebo. Tesamorelin produced no significant effects on abdominal subcutaneous adipose tissue, fasting glucose, 2-hour glucose or HbA1c levels. Tesamorelin did significantly increase mean insulin-like growth factor-1 ( IGF-1) levels by 90% compared to placebo. There were no serious adverse events and the most common adverse events reported were hypertension, hyperglycemia, tingling/paresthesia and peripheral edema. Data were presented at the Endocrine Society meeting in Houston. ...